Healthcare Industry News: HSMN NewsFeed
News Release - February 6, 2017
BioVentrix Announces NUB Reimbursement Status 1 for Revivent TC(TM) TransCatheter Ventricular Enhancement System in GermanySAN RAMON, Calif., Feb. 6, 2017 -- (Healthcare Sales & Marketing Network) -- BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced that InEk, the German Institute for the Hospital Remuneration System, has awarded NUB Status 1 for the Revivent TC™ TransCatheter Ventricular Enhancement System.
The NUB process supports introduction of new and innovative medical devices in Germany. It allows participating hospitals to receive full reimbursement and a supplemental payment for new technologies in the German reimbursement system. NUB Status 1 is the highest priority designation available, and was only assigned to a small minority of product submissions for 2017.
"Achieving NUB Reimbursement Status 1 is an important step towards increasing product adoption in Germany, where there's a growing need for effective, less invasive, and cost-effective HF treatment options such as Revivent TC," stated Kenneth Miller, president and chief executive officer of BioVentrix, Inc. "We look forward to working closely with physicians and hospitals to bring this novel therapy to patients suffering from left ventricular dysfunction."
About BioVentrix and the Revivent TC System
BioVentrix, a privately held medical technology company headquartered in San Ramon, Calif., is focused on developing and commercializing minimally invasive therapies for treating HF. The company recently received CE mark certification for its closed-chest Revivent TC TransCatheter Ventricular Enhancement System for plication of scar tissue in post-MI, ischemic cardiomyopathy patients. Placement of the Revivent TC System via the LIVE procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a catheter-based approach. The anchors are then pulled towards one another, effectively excluding the scarred and non-functioning heart wall. Ventricular volume is immediately reduced as a result of the exclusion, by as much as 30-40 percent1.
Note: The Revivent TC System is approved for sale in Europe; it is not approved for sale in the United States.
1. Wechsler, A. et al., Clinical benefits twelve months after less invasive ventricular restoration operations without ventriculotomy. Annual meeting of the European Society of Cardio-Thoracic Surgery, 07 Oct. 2013, Vienna, Austria.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBioVentrix announces the 1st Revivent TC(TM) TransCatheter commercial procedure to treat Ischemic Cardiomyopathy in China
BioVentrix Announces the 1st Revivent TC(TM) TransCatheter Ventricular Enhancement Procedure in Germany After Receiving CE-Mark Certification
Steven Healy appointed as Chairman of the Board of Directors of BioVentrix, Inc.